J3389 HCPCS Level II code: Topical administration, prademagene zamikeracel, per treatment
J3389 is the HCPCS code for “Topical administration, prademagene zamikeracel, per treatment” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J3389Topical administration, prademagene zamikeracel, per treatment
Short description: Topi adm prad zami per treat
HCPCS · United States
Medicare details
The indicators CMS publishes with J3389 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Drugs
- Type of service
- Medical care
- BETOS category
- Other drugs
- Added
- Jan 1, 2026
Where J3389 sits
- 1J codesDrugs administered other than orally
- 2Active code J3389Topical administration, prademagene zamikeracel, per treatment
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J3389 mean?
J3389 is the HCPCS code for “Topical administration, prademagene zamikeracel, per treatment” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J3389?
CMS lists J3389’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J3389
All J codesJ3376Injection, vancomycin hcl (hikma), not therapeutically equivalent to j3373, 10 mgJ3379Injection, valproate sodium, 5 mgJ3380Injection, vedolizumab, intravenous, 1 mgJ3385Injection, velaglucerase alfa, 100 unitsJ3386Injection, etuvetidigene autotemcel, per treatmentJ3387Injection, elivaldogene autotemcel, per treatmentJ3391Injection, atidarsagene autotemcel, per treatmentJ3392Injection, exagamglogene autotemcel, per treatmentJ3393Injection, betibeglogene autotemcel, per treatmentJ3394Injection, lovotibeglogene autotemcel, per treatmentJ3396Injection, verteporfin, 0.1 mgJ3397Injection, vestronidase alfa-vjbk, 1 mg